Chemotherapeutic Strategies for Advanced NSCLC in the Era of Personalized Medicine: A Focus on Platinum-Refractory Disease

The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC that do not have an actionable mutation target and have progressed on or after prior platinum-based therapy.

Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females.

This activity will highlight the ever-present role of chemotherapeutic strategies specifically in the platinum-refractory setting and its role in improving outcomes including survival and quality of life, including available treatment options, selecting the most appropriate therapy for these patients, and how clinical and biomarker data may inform selection of available treatment options.


Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative represent the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies.

Endocrine therapy is currently the cornerstone of treatment for advanced HR-positive breast cancer. However, not all patients respond to first-line endocrine therapy, and those that do respond eventually experience disease relapse. Resistance to endocrine therapy is common, and complete disease resistance to additional endocrine therapy eventually develops in patients with HR-positive metastatic breast cancer (MBC). The 5-year and 10-year survival rates for MBC are 26% and 5% to 10%, respectively. Significant therapeutic advances in this area include the development of agents that target critical pathways involved in the development of resistance to endocrine therapy. These include mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors.   ENROLL IN THIS ACTIVITY


Nursing Clinical Insights Into the Benefits and Challenges of EGFR TKIs in the Treatment of NSCLC

Lung cancer is the leading cause of cancer death. Approximately 85% of lung cancer cases are non–small cell lung cancer (NSCLC), 10% to 15% of which are epidermal growth factor receptor (EGFR) mutation positive. The development of EGFR inhibitors (eg, tyrosine kinase inhibitors [TKIs]) has led to targeted therapy, advancing the management of NSCLC. Unfortunately, the disease often develops resistance to some of these therapies; however, significant progress has been made in the treatment of NSCLC.

Recent advances in next-generation EGFR TKIs have shown promising results in patients with EGFR mutation–positive refractory NSCLC.



Understanding Treatment Strategies for Squamous Cell Carcinoma of the Head and Neck

The complexity of managing squamous cell carcinoma of the head and neck (SCCHN) requires a multidisciplinary team. Support and services for the treatment of patients with SCCHN may include nutritional support, speech and swallowing therapy, and dental care, among others.  Additionally, the American Cancer Society published new guidelines for head and neck cancer survivorship care in March 2016.

The goal of this activity is to close educational gaps by providing clinicians with the latest evidence-based data about current and emerging agents and multidisciplinary approaches for the treatment of squamous cell carcinoma of the head and neck.  ENROLL IN THIS ACIVITY


Managing Unresectable Hepatocellular Carcinoma: Focus on Systemic Therapies

Advances in the understanding of the molecular pathogenesis of hepatocellular carcinoma (HCC) have broadened the potential for effective molecular targeted therapies. However, the management of unresectable HCC continues to be challenging. It is important that healthcare providers involved in the management of HCC have a good understanding of the current therapeutic options and that they stay up-to-date regarding the emerging therapies for unresectable disease.  However, in light of the complexity of treatment and the rapid pace of treatment-related developments, this can be a difficult goal to achieve and maintain. 

This activity will provide updates on approved and investigational therapies for unresectable HCC, discuss the importance of multidisciplinary and interprofessional collaboration, and present useful tips on using a shared decision-making approach in the management of HCC. 

Paving the Way to Better Choices for Veterans With Lung Cancer: A Shared Decision-Making Approach to Treatment

Approximately 35,000 new cases of cancer occur in military veterans each year; cancer is the second leading cause of death among military veterans. According to the late Rear Admiral Philip J. Coady, USN, former Chairman of the Board of Directors of the Lung Cancer Alliance, “lung cancer is an urgent priority among veterans. 

Because clinicians who work in VA facilities may not realize the importance of patient engagement and SDM with veterans and their caregivers, education will also be provided to assist clinicians in engaging military veterans in treatment decisions using SDM approaches and prioritizing the timeliness of care, coordination of care, screening, and access to palliative care for military veterans.  VIEW THIS ACTIVITY


Failure Is Not an Option: Selecting Optimal Stem Cell Mobilization Strategies for Multiple Myeloma and Non-Hodgkin Lymphoma

There are many opportunities for healthcare professionals to improve the probability of successful mobilization in their patients with MM or NHL who are eligible for aHSCT. This activity will address available mobilization regimens for stem cell collection, identifying patients at risk for poor mobilization, and guidance for optimal regimen selection for each of their patients based on patient characteristics and cost of treatment. 

This activity is intended for medical oncologists, oncology nurses, transplant specialists, and other healthcare providers who treat or manage patients under consideration for stem cell mobilization and transplantation.  ENROLL IN THIS ACIVITY


Conquering Therapeutic Challenges in Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex: The Power of mTOR Inhibition

The goal of this activity is to close knowledge gaps on how to effectively treat and manage subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) and to provide clinicians with the necessary information to confidently use current and emerging agents to reduce symptoms while minimizing adverse effects. 

TSC is an autosomal dominant genetic disorder characterized by the systemic growth of benign, noninvasive legions, or hamartomas. Common sites of lesion growth include the brain, skin, kidney, heart, lung, and liver. TSC is frequently diagnosed before patients are 15 months old. The central nervous system is the most commonly affected system, affecting 85% to 90% of children and adolescents.  ENROLL IN THIS ACTIVITY


Transforming the Quality of Care for Patients With Immune Thrombocytopenia: Therapeutic and Management Approaches Making a Difference

Immune thrombocytopenia (ITP), once known as idiopathic thrombocytopenic purpura, is an autoimmune disorder that can occur acutely or chronically, and ranges in severity from mild to life-threatening. 

New treatments for both adults and children with ITP are continuously becoming available, challenging clinicians to optimally balance efficacy and safety when developing individualized treatment plans. This Virtual Grand Rounds initiative aims to close educational gaps and provide clinicians with up-to-date knowledge on current and emerging treatment strategies to make informed clinical choices to confidently treat and manage ITP.  ENROLL IN THIS ACTIVITY


Defining Personalized Treatment Approaches in NSCLC: The Significance of EGFR Mutations

Non–small cell lung cancer is the most common form of lung cancer, accounting for more than 80% of newly diagnosed cases, with most patients having advanced stage disease. In adenocarcinomas, epidermal growth factor receptor (EGFR) gene mutations are prevalent in 10% of Western patients and in up to 50% of Asian patients.

Mutation analysis of the EGFR gene is an essential part of the diagnostic algorithm in patients with metastatic or recurrent NSCLC. EGFR mutation testing is recommended in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for metastatic NSCLC so that patients with this genetic abnormality can receive appropriate and effective targeted treatment.   VIEW THIS ACTIVITY


Recent Courses

There is currently no content to view in this section.

Subscribe and receive timely updates

Returning AXIS Users

If you are an active member, this site has been updated with enhanced functionality and security. You will need to create a new user profile and password. We apologize for any inconvenience this may cause. We truly appreciate you using to meet your educational needs.

View the Courses You Have Completed

    Please login or create an account to view your activities.